+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The endocannabinoid system and its therapeutic exploitation in multiple sclerosis: Clues for other neuroinflammatory diseases



The endocannabinoid system and its therapeutic exploitation in multiple sclerosis: Clues for other neuroinflammatory diseases



Progress in Neurobiology 160: 82-100



Multiple sclerosis is the most common inflammatory demyelinating disease of the central nervous system, caused by an autoimmune response against myelin that eventually leads to progressive neurodegeneration and disability. Although the knowledge on its underlying neurobiological mechanisms has considerably improved, there is a still unmet need for new treatment options, especially for the progressive forms of the disease. Both preclinical and clinical data suggest that cannabinoids, derived from the Cannabis sativa plant, may be used to control symptoms such as spasticity and chronic pain, whereas only preclinical data indicate that these compounds and their endogenous counterparts, i.e. the endocannabinoids, may also exert neuroprotective effects and slow down disease progression. Here, we review the preclinical and clinical studies that could explain the therapeutic action of cannabinoid-based medicines, as well as the medical potential of modulating endocannabinoid signaling in multiple sclerosis, with a link to other neuroinflammatory disorders that share common hallmarks and pathogenetic features.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 060347326

Download citation: RISBibTeXText

PMID: 29097192

DOI: 10.1016/j.pneurobio.2017.10.007


Related references

Activation of the endocannabinoid system as therapeutic approach in a murine model of multiple sclerosis. Faseb Journal 19(10): 1338-1340, 2005

The Endocannabinoid System in Peripheral Lymphocytes as a Mirror of Neuroinflammatory Diseases. Current Pharmaceutical Design 14(23): 2370-2382, 2008

The endocannabinoid system in peripheral lymphocytes as a mirror of neuroinflammatory diseases. Current Pharmaceutical Design 14(23): 2370-2342, 2008

Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide. European Journal of Neuroscience 28(4): 633-641, 2008

Lymphatic system and gut microbiota affect immunopathology of neuroinflammatory diseases, including multiple sclerosis, neuromyelitis optica and Alzheimer's disease. Clinical and Experimental Neuroimmunology 8(3): 177-179, 2017

The Role of Macrophages in Neuroinflammatory and Neurodegenerative Pathways of Alzheimer's Disease, Amyotrophic Lateral Sclerosis, and Multiple Sclerosis: Pathogenetic Cellular Effectors and Potential Therapeutic Targets. International Journal of Molecular Sciences 19(3), 2018

Neuroinflammatory diseases with a focus on multiple sclerosis - an overview. Drug Research 63(Suppl. 1): S3-S4, 2014

The endocannabinoid system in the inflammatory and neurodegenerative processes of multiple sclerosis and of amyotrophic lateral sclerosis. Experimental Neurology 224(1): 92-102, 2010

Cytokines as novel therapeutic agents for neuroinflammatory disorders A role for interferon-beta in the treatment of multiple sclerosis. Current Medicinal Chemistry - Central Nervous System Agents 1(3): 201-208, 2001

The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation. Pharmacological Research 60(2): 77-84, 2009

Endocannabinoid signaling and neuroinflammatory diseases. Current Pharmaceutical Design 14(23): 2252-2253, 2008

The Endocannabinoid System and Multiple Sclerosis. Current Pharmaceutical Design 14(23): 2326-2336, 2008

The endocannabinoid system and multiple sclerosis. Current Pharmaceutical Design 14(23): 2326-2336, 2008

Characterization of variations in IL23A and IL23R genes: possible roles in multiple sclerosis and other neuroinflammatory demyelinating diseases. Aging 8(11): 2734-2746, 2016

Potential control of multiple sclerosis by cannabis and the endocannabinoid system. Cns & Neurological Disorders Drug Targets 11(5): 624-641, 2012